For the quarter ended September 2025, Ashland (ASH) reported revenue of $478 million, down 8.4% over the same period last year. EPS came in at $1.08, compared to $1.26 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $474.31 million, representing a surprise of +0.78%. The company delivered an EPS surprise of -7.69%, with the consensus EPS estimate being $1.17.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Intermediates: $33 million compared to the $34.02 million average estimate based on three analysts. The reported number represents a change of -8.3% year over year.
- Revenue- Life Sciences: $173 million versus the three-analyst average estimate of $172.37 million. The reported number represents a year-over-year change of -9.9%.
- Revenue- Personal Care: $151 million versus the three-analyst average estimate of $148.43 million. The reported number represents a year-over-year change of -6.8%.
- Revenue- Specialty Additives: $131 million compared to the $129.29 million average estimate based on three analysts. The reported number represents a change of -9% year over year.
- Revenue- Intersegment sales: $-10 million versus the two-analyst average estimate of $-10 million. The reported number represents a year-over-year change of -16.7%.
- Adjusted EBITDA- Life Science: $55 million versus $55.19 million estimated by three analysts on average.
- Adjusted EBITDA- Personal Care: $43 million compared to the $43.03 million average estimate based on three analysts.
- Adjusted EBITDA- Specialty Additives: $29 million versus $25.71 million estimated by three analysts on average.
- Adjusted EBITDA- Intermediates: $5 million compared to the $6.45 million average estimate based on three analysts.
- OPERATING INCOME- Unallocated and other: $-11 million versus $-14.25 million estimated by two analysts on average.
View all Key Company Metrics for Ashland here>>>
Shares of Ashland have returned -1.6% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ashland Inc. (ASH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
